نتایج جستجو برای: chimerism

تعداد نتایج: 2215  

2012
David A. Leonard Duncan A. McGrouther Josef M. Kurtz Curtis L. Cetrulo

Since the start of the clinical vascularized composite allotransplantation (VCA) era over a decade ago this field has witnessed significant developments in both basic and translational research. Transplant tolerance, defined as rejection-free acceptance of transplanted organs or tissues without long-term immunosuppression, holds the potential to revolutionize the field of VCA by removing the ne...

Journal: :Blood 2011
Satoru Otsuru Valeria Rasini Rita Bussolari Ted J Hofmann Massimo Dominici Edwin M Horwitz

Transplantation of whole bone marrow (BMT) leads to engraftment of both osteoprogenitor cells and hematopoietic cells; however, the robust osteopoietic chimerism seen early after BMT decreases with time. Using our established murine model, we demonstrate that a post-BMT regimen of either granulocyte-colony stimulating factor, growth hormone, parathyroid hormone, or stem cell factor each stimula...

2013
Giuseppe Visani Paola Picardi Barbara Guiducci Federica Loscocco Claudio Giardini Moira Lucesole Sara Barulli Teresa Ricciardi Alessandro Isidori

A 9-year-old female received an allogeneic stem cell transplant (SCT) from an ABO-incompatible HLA-matched sibling for β-thalassemia major, without achieving a complete donor chimerism. Subsequently, the patient received five donor lymphocyte infusions, without increasing donor chimerism, and autologous SCT. Due to the persistent bone marrow aplasia, the patient received a second allogeneic SCT...

Journal: :Veterinary immunology and immunopathology 2003
Kate E Creevy Thomas R Bauer Laura M Tuschong Lisa J Embree Andrew M Silverstone John D Bacher Chris Romines Julie Garnier Marvin L Thomas Lyn Colenda Dennis D Hickstein

The genetic disease canine leukocyte adhesion deficiency (CLAD) is characterized by recurrent, severe bacterial infections, typically culminating in death by 6 months of age. CLAD is due to a mutation in the leukocyte integrin CD18 subunit, which prevents surface expression of the CD11/CD18 leukocyte integrin complex. We demonstrate that stable mixed donor:host hematopoietic chimerism, achieved...

Journal: :Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012
Amir A Toor Roy T Sabo Harold M Chung Catherine Roberts Rose H Manjili Shiyu Song David C Williams Wendy Edmiston Mandy L Gatesman Richard W Edwards Andrea Ferreira-Gonzalez William B Clark Michael C Neale John M McCarty Masoud H Manjili

Patients with hematologic malignancies were conditioned using a rabbit antithymocyte globulin-based reduced-intensity conditioning regimen for allogeneic stem cell transplantation. Donor-derived CD3(+) cell count (ddCD3), a product of CD3(+) cell chimerism and absolute CD3(+) cell count, when <110/μL at 8 weeks post-stem cell transplantation predicted a high risk of sustained mixed chimerism an...

Journal: :The Japanese journal of veterinary research 1965
H Kanagawa J Muramoto K Kawata T Ishikawa

2005
Terry B. Strom Xin Xiao Zheng Sophoclis P. Alexopoulos Christophe Mariat Megan Sykes Christoph Domenig Alberto Sanchez-Fueyo Josef Kurtz

Journal: :Blood 2002
Satoshi Hayashi William H Peranteau Aimen F Shaaban Alan W Flake

In utero hematopoietic stem cell transplantation (IUHSCTx) can achieve mixed hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning or immunosuppression. The primary limitation to the clinical application of IUHSCTx has been minimal donor cell engraftment, well below therapeutic levels for most target diseases. Donor lymphocyte infusion (DLI) has been used in po...

Journal: :Blood 2016
Rebecca A Marsh Adam Lane Parinda A Mehta Lisa Neumeier Sonata Jodele Stella M Davies Alexandra H Filipovich

Reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) with alemtuzumab, fludarabine, and melphalan is an effective approach for patients with nonmalignant disorders. Mixed chimerism and graft-versus-host-disease (GVHD) remain limitations on success. We hypothesized that higher levels of alemtuzumab at day 0 would result in a low risk of acute GVHD, a higher ri...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید